| Inventor | Institute |
|---|---|
| Jorgen Fogh | Memorial Sloan-Kettering Cancer Center (MSK) |
| SKU: | 161928 |
|---|---|
| Product description: | HT-144 is a malignant human melanoma cell line that displays aneuploid fibroblastic morphology and grows in adherent tissue culture. This cell line has been reported to be nonpermissive for human cytomegalovirus (HCMV). HT-144 cells form xenograft tumours when injected into immunocompromised mice. These cells contain a mutation in the ATM gene, resulting in the expression of a truncated protein, which causes increased sensitivity to UVB and ionising radiation compared to other melanoma cell lines. The HT-144 cells also express mutant B-Raf (V600E). |
| Products or characteristics of interest: | Karyotype – (P15) hypotriploid to hypertriploid (+A, +B, +C, +D, +E, +F, +G) with abnormalities including acrocentric fragments, minutes, secondary constrictions, breaks, large submetacentric, subtelocentric and minute markers. Tumorigenic – Yes, in nude mice; forms anaplastic malignant tumor consistent with melanoma; tumors also form in steroid treated hamsters. Isoenzymes: AK-1, 1; ES-D, 1-2; G6PD, B; GLO-I, 2; PGM1, 1-2; PGM3, 1 |
| Cat. #: | 161928 |
|---|---|
| Cancer types: | Skin cancer |
| Tissue: | Subcutaneous tissue |
| Morphology: | Aneuploid fibroblastic |
| Growth properties: | Adherent |
| Cancer Types In Detail: | Melanoma |
| Primary citation: | Fogh et al. 1977. Journal of the National Cancer Institute. 58: 209-214. PMID: 833871. |
| Shipping conditions: | Dry Ice |
|---|---|
| Growth medium: | McCoy’s 5a Medium Modified with fetal bovine serum to a final concentration of 10%. |
| Temperature: | 37° C |
| Atmosphere: | 5% CO2 in air |
| Storage medium: | Complete growth medium supplemented with 5% DMSO |
| Biosafety level: | 1 |
| References: |
Frohlich et al. 2023. Cancer Research Communications. 3(9). PMID: 37674529. |
|---|
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.